ERBB2 and breast carcinoma: Hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) breast cancer represents approximately 60% of all breast cancer cases and is generally responsive to endocrine therapy (ET), leading to favorable clinical outcomes [1, 2].